Literature DB >> 17722270

Quantum chemical analysis of the deferiprone-iron binding reaction.

Viroj Wiwanitkit1.   

Abstract

To prevent side effects of excessive accumulation of iron in the body, chelation therapy is recommended in transfusion-dependent patients. The reaction between deferiprone and iron to form a complex red substance can be described as 3 molecules of the chelator, deferiprone, reacting with a molecule of iron. However, the actual mechanism of the deferiprone-iron binding reaction is not well understood. A quantum chemical analysis of the deferiprone-iron binding reaction was performed, focusing on the reaction between 1 molecule of deferiprone and I molecule of iron. The two main alternative pathways for the deferiprone-iron binding reaction were shown to be C-C cleavage and C-O cleavage. The required energy for complex formation in C-C cleavage was less than for C-O cleavage. The total energy requirement for C-C cleavage was negative, implying that this reaction can occur without any external energy source. The resulting complex fits the reported tertiary structure model for the deferiprone-iron complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17722270      PMCID: PMC2426763          DOI: 10.2147/nano.2006.1.1.111

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


Introduction

To prevent the side effects of excessive accumulation of iron in the body, chelation therapy is recommended in transfusion-dependent patients (Ceci et al 2003; Marx 2003). Pharmacologically, the tight binding of chelators to iron blocks the iron’s ability to catalyze redox reactions (Ceci et al 2003). Consequently, a chelator that binds to all binding sites of the iron completely inactivates the free iron. The two common iron-chelating agents available for the treatment of iron overload are deferoxamine and deferiprone (Ceci et al 2003). Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload (Nagarajan et al 2005). It is indicated as a second-line treatment in patients with thalassaemia major, for whom deferoxamine therapy is contraindicated, or in patients with serious toxicity to deferoxamine therapy (Ceci et al 2003). The reaction between deferiprone and iron to form a complex red substance can be described as three molecules of the chelator, deferiprone, reacting with one molecule of iron. However, the actual mechanism of the deferiproneiron binding reaction is not well described. This paper reports a quantum chemical analysis of the deferiproneiron binding reaction.

Materials and methods

Alternative pathways for deferiprone–iron binding reaction

Deferiprone is a bidentate chelator: a single molecule can interact with only two of the coordination sites on iron (Figure 1). Therefore, 3 molecules are required for complete binding. This study focused on the reaction between 1 molecule of deferiprone and 1 molecule of iron. The two main alternative pathways for the deferiproneiron binding reaction are C-C cleavage and C-O cleavage.
Figure 1

The alternative pathways for the deferiprone–iron binding reaction.

The alternative pathways for the deferiproneiron binding reaction.

Quantum chemical analysis for bonding energy

The quantum chemical analysis for bonding energy of deferiprone (C7H9NO2) was performed according to classical bonding theory (Goldberg 1989). The resulting complexes between deferiprone and iron from each alternative reaction pathway were analyzed, and the required energy for complex formation by each pathway was compared.

Results

The details and the required energy for complex formation in C-C cleavage and C-O cleavage pathways are presented in Table 1. The required energy for complex formation in C-C cleavage was less than for C-O cleavage.
Table 1

Details and required energy for complex formation in C-C cleavage and C-O cleavage pathways

ItemsC-C cleavageC-O cleavage
Bond breaking*1 C=C, 1 C=O1 C=O
Bond forming2 C-O, 1 C-H, 1 C-C, 1 C-Fe2+1 C-O, 1 C-Fe2+
Accumulated energy146 kcal/mol + 177 kcal/mol177 kcal/mol
Released energy(2 × 83 kcal/mol) + 100 kcal/mol + 80 kcal/mol + 1 eV83 kcal/mol + 1 eV
Required energy−23 kcal/mol − 1 eV94 kcal/mol − 1 eV

bond-breaking accumulated energy

bond-forming released energy

required energy = accumulated energy − released energy

Abbreviations: eV, electron volt

Details and required energy for complex formation in C-C cleavage and C-O cleavage pathways bond-breaking accumulated energy bond-forming released energy required energy = accumulated energy − released energy Abbreviations: eV, electron volt

Discussion

The recommended treatment for many congenital hematological disorders, especially for thalassaemia major, is regular blood transfusions. These transfusions lead to the harmful accumulation of iron in the body and subsequent hemochromatosis (Ceci 2003). Iron chelation is required in these cases. Deferiprone is a new oral iron-chelating agent which is effective in removing iron from the heart, which is the target organ of iron toxicity and mortality in iron-loaded thalassaemia patients (Kontoghiorghes et al 2003). Biochemically, deferiprone is a bidentate chelator. Because a single molecule can interact with only 2 of the coordination sites on iron, 3 molecules are required for complete binding (Merson and Oliver 2002; Kontoghiorghes et al 2003). The crystal structure of deferiprone is orthorhombic (Chan et al 1992). In each molecule, the OH group and the CO oxygen are insignificantly intramolecularly hydrogen-bonded (Chan et al 1992). The fundamental intermolecular and insignificant intramolecular hydrogen-bonded dimer structure of deferiprone is maintained, but is distorted and supplemented by hydrogen bonds between the CO oxygen of each deferiprone molecule and the OH group of one formic acid molecule (Chan et al 1992). Tam et al (2003) noted that future chelator research would focus on the application of chelators for other diseases and the development of new effective chelators. Evidence on the differences in the mode of action of chelators, and molecular structure – activity correlations, is valuable for future metallopharmacological studies (Kontoghiorghes et al 2004). Therefore, research on the biochemical reaction in deferiproneiron complex formation can provide useful information for further bio-iron research. In the present study, 2 possible mechanisms are proposed for deferiproneiron complex formation. The energy required for C-C cleavage was much less than for C-O cleavage. In addition, the total energy requirement for C-C cleavage was negative, implying that this reaction can occur without any external energy source. The resulting complex fits the reported tertiary structure model for the deferiproneiron complex (Wiwanitkit 2005).
  8 in total

Review 1.  Pathophysiology and treatment of iron overload in thalassemia patients in tropical countries.

Authors:  J J M Marx
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

2.  Enrichment of ligands for the serotonin receptor using the Shape Signatures approach.

Authors:  Karthigeyan Nagarajan; Randy Zauhar; William J Welsh
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

Review 3.  Iron chelator research: past, present, and future.

Authors:  Tim F Tam; Regis Leung-Toung; Wanren Li; Yingsheng Wang; Khashayar Karimian; Michael Spino
Journal:  Curr Med Chem       Date:  2003-06       Impact factor: 4.530

Review 4.  Orally active iron chelators.

Authors:  L Merson; N Olivier
Journal:  Blood Rev       Date:  2002-06       Impact factor: 8.250

Review 5.  The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

Authors:  G J Kontoghiorghes; K Pattichis; K Neocleous; A Kolnagou
Journal:  Curr Med Chem       Date:  2004-08       Impact factor: 4.530

Review 6.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Crystal structures of a new oral iron chelator, 1,2-dimethyl-3-hydroxy-4-pyridone, and its solvates with acetic acid and formic acid.

Authors:  H K Chan; S Ghosh; S Venkataram; Y E Rahman; D J Grant
Journal:  J Pharm Sci       Date:  1992-04       Impact factor: 3.534

Review 8.  Pharmacotherapy of iron overload in thalassaemic patients.

Authors:  Adriana Ceci; Mariagrazia Felisi; Vincenzo De Sanctis; Domenico De Mattia
Journal:  Expert Opin Pharmacother       Date:  2003-10       Impact factor: 3.889

  8 in total
  3 in total

1.  Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice.

Authors:  Zhenyou Zou; Shengxi Shao; Ruyi Zou; Jini Qi; Liguan Chen; Hui Zhang; Qiqiong Shen; Yue Yang; Liman Ma; Ruzeng Guo; Hongwen Li; Haibo Tian; Pengxin Li; Mingfang Yu; Lu Wang; Wenjuan Kong; Caiyu Li; Zhenhai Yu; Yuping Huang; Li Chen; Qi Shao; Xinyan Gao; Xiaolin Chen; Zhengbo Zhang; Jianguo Yan; Xiaoyun Shao; Ru Pan; Lu Xu; Jing Fang; Lei Zhao; Yaohui Huang; Anqi Li; Yuchong Zhang; Wenkao Huang; Kechun Tian; Minxin Hu; Linchao Xie; Lingbin Wu; Yu Wu; Zhen Luo; Wenxin Xiao; Shanshan Ma; Jianan Wang; Kaixin Huang; Siyuan He; Fan Yang; Shuni Zhou; Mo Jia; Hui Zhang; Hongsheng Lu; Xinjuan Wang; Jie Tan
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-06

2.  Generation of reactive oxygen species by hydroxypyridone compound/iron complexes.

Authors:  Keiko Murakami; Masataka Yoshino
Journal:  Redox Rep       Date:  2020-12       Impact factor: 4.412

3.  Inflammation and ER stress downregulate BDH2 expression and dysregulate intracellular iron in macrophages.

Authors:  Susu M Zughaier; Brandon B Stauffer; Nael A McCarty
Journal:  J Immunol Res       Date:  2014-12-01       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.